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2398Inherited Genetic Variants Associated with
Melanoma BRAF/NRAS Subtypes
Nancy E. Thomas1,2, Sharon N. Edmiston1,2, Irene Orlow3, Peter A. Kanetsky4, Li Luo5,
David C. Gibbs6, Eloise A. Parrish1,2, Honglin Hao1, Klaus J. Busam7, Bruce K. Armstrong8,
Anne Kricker9, Anne E. Cust9,10, Hoda Anton-Culver11, Stephen B. Gruber12, Richard P. Gallagher13,
Roberto Zanetti14, Stefano Rosso14, Lidia Sacchetto14,15, Terence Dwyer16, David W. Ollila2,17,
Colin B. Begg3, Marianne Berwick5 and Kathleen Conway1,2,18, on behalf of the GEM Study GroupBRAF and NRAS mutations arise early in melanoma development, but their associations with low-penetrance
melanoma susceptibility loci remain unknown. In the Genes, Environment and Melanoma Study, 1,223
European-origin participants had their incident invasive primary melanomas screened for BRAF/NRAS muta-
tions and germline DNA genotyped for 47 single-nucleotide polymorphisms identified as low-penetrant
melanoma-risk variants. We used multinomial logistic regression to simultaneously examine each single-
nucleotide polymorphism’s relationship to BRAF V600E, BRAF V600K, BRAF other, and NRASþ relative to
BRAFe/NRASe melanoma adjusted for study features. IRF4 rs12203592*T was associated with BRAF V600E (odds
ratio [OR] ¼ 0.59, 95% confidence interval [CI] ¼ 0.43e0.79) and V600K (OR ¼ 0.65, 95% CI ¼ 0.41e1.03), but not
BRAF other or NRASþmelanoma. A global test of etiologic heterogeneity (Pglobal ¼ 0.001) passed false discovery
(Pglobal ¼ 0.0026). PLA2G6 rs132985*T was associated with BRAF V600E (OR ¼ 1.32, 95% CI ¼ 1.05e1.67) and BRAF
other (OR ¼ 1.82, 95% CI ¼ 1.11e2.98), but not BRAF V600K or NRASþ melanoma. The test for etiologic
heterogeneity (Pglobal) was 0.005. The IRF4 rs12203592 associations were slightly attenuated after adjustment for
melanoma-risk phenotypes. The PLA2G6 rs132985 associations were independent of phenotypes. IRF4 and
PLA2G6 inherited genotypes may influence melanoma BRAF/NRAS subtype development.
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an oINTRODUCTION
Genome-wide association studies and candidate pathway
studies have identified low-penetrant genetic variants asso-
ciated with melanoma risk. Many of these variants are in
gene regions associated with pigmentation, such as TYRP1,
TYR, HERC2/OCA2, SLC45A2, and ASIP; nevi, such as
PLA2G6, MTAP, and NID1; or both, such as IRF4, whereas
others are in genes, including ATM, MX2, PARP1, ARNT, and
CASP8, not associated with melanoma-risk phenotypes
(Amos et al., 2011; Barrett et al., 2011; Bishop et al., 2009;
Fernandez et al., 2008; Gudbjartsson et al., 2008; Han
et al., 2008; Jannot et al., 2005; Law et al., 2012;
Macgregor et al., 2011; Nan et al., 2011; Zhang et al.,
2012). In parallel but separate studies, we and Hacker et al.
found that the increased number of nevi was associated with
melanoma BRAF V600E and V600K subtypes (Hacker et al.,
2016; Thomas et al., 2007, 2017), and we found that BRAF
V600E was associated with blond and/or light brown hair and
BRAF V600K with less freckling (Thomas et al., 2017).MC1R
has been inconsistently associated with BRAF V600E cases
(Fargnoli et al., 2008; Hacker et al., 2010, 2013, 2016; Landi
et al., 2006; Thomas et al., 2010a). Our recent work indicates
that MC1R variants are positively associated with BRAF
V600E cases in people with darker phenotypes, but inversely
associated with BRAF V600K cases with no significant effect
modification by phenotype (Thomas et al., 2017). To our
knowledge, the associations between melanoma BRAF/NRAS
subtypes and other low-penetrant genetic variants besides
MC1R have not been investigated.s. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology. This is
pen access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1. Characteristics of 1,223 participants with
incident primary invasive cutaneous melanoma
analyzed for BRAF/NRAS subtype in the GEM Study1
Characteristic No. (%)
Age at diagnosis, y
Median (IQR) 60 (24)
Sex
Male 728 (59.5)
Female 495 (40.5)
Country
North America 471 (38.5)
Australia 752 (61.5)
Lesion status
First primary melanoma 908 (74.2)
Second- or higher-order primary melanoma 315 (25.8)
NRAS/BRAF subtype
BRAFþ 322 (26.3)
BRAF V600E 219 (17.9)
BRAF V600K 68 (5.6)
BRAF other2 35 (2.9)
NRASþ 165 (13.5)
WT (BRAFe/NRASe) 736 (60.2)
Breslow thickness, mm
Median (IQR), mm 0.70 (0.83)
Histologic subtype
Superficial spreading melanoma 830 (67.9)
Nodular melanoma 104 (8.5)
Lentigo maligna melanoma 184 (15.0)
Other 105 (8.6)
No. of back nevi
0e4 430 (35.7)
5e10 297 (24.7)
11e25 261 (21.7)
>25 215 (17.9)
Hair color
Dark brown/black 337 (27.6)
Blonde/light brown 772 (63.3)
Red 111 (9.1)
Freckling
None 505 (43.0)
Few 521 (44.4)
Many 148 (12.6)
Abbreviations: GEM, Genes, Environment and Melanoma; IQR,
interquartile range; WT, wild type.
1Limited to individuals of European origin. Counts may not sum to the
total number of study subjects due to missing data.
2BRAF other included L584F (n ¼ 1), D594G (n ¼ 2), D594N (n ¼ 6),
L597K (n ¼ 1), L597R (n ¼ 1), L597S (n ¼ 1), V600D (n ¼ 4), V600R (n ¼
9), K601E (n ¼ 5), K601N (n ¼ 2), R603Q (n ¼ 1), G606E (n ¼ 1), and the
compound deletion VKS600-602D (n ¼ 1).
NE Thomas et al.
Inherited Variants and Melanoma BRAF/NRAS SubtypesWe studied low-penetrant melanoma-risk variants in the
Genes, Environment and Melanoma (GEM) Study, a large
international population-based study of incident melanoma
(Begg et al., 2006; Millikan et al., 2006), in relationship to
melanoma BRAF/NRAS subtypes. Participants’ germline
DNAwas genotyped for 47 single-nucleotide polymorphisms
(SNPs) from 21 distinct genomic regions, and their invasive
primary melanomas were analyzed for BRAF and NRAS
mutations. For each SNP, we used multinomial logistic
regression to simultaneously assess its association with BRAF
V600E, BRAF V600K, BRAF other, and NRASþ, compared
with wild-type (WT; BRAFe/NRASe) melanoma adjusted for
study features: age at diagnosis, sex, study center, and
whether first- or higher-order primary melanoma.
RESULTS
Subject characteristics
In GEM, 1,223 participants of European origin had their
incident cutaneous invasive primary melanomas analyzed for
BRAF and NRAS mutations. The median age was 60 years;
59.5% were male; and 61.5% were from Australia and
38.5% from the United States (Table 1). These 1,223 mela-
nomas (all from different patients) were from 908 patients
(74.2%) who had only one melanoma at the time of
recruitment (a first primary melanoma) and 315 patients
(25.8%) who had more than one melanoma at the time of
recruitment. For the latter group of patients, we retrieved and
utilized for these analyses the 315 second- or higher-order
primary melanomas that prompted their recruitment into
GEM. The melanomas were 17.9% BRAF V600E, 5.6% BRAF
V600K, 2.9% BRAF other, 13.5% NRASþ, and 60.2% WT.
Each of these mutations was exclusive of the others. The
predominant subtype was superficial spreading melanoma
(67.9%). The median Breslow thickness was 0.70 mm. Of the
1,223 participants, 24.7% had 0e4, 21.7% had 11e25, and
17.9% had >25 nevi on their back. Blond or light brown was
the natural hair color of a majority (63.3%) of the partici-
pants; 9.1% had red hair. A few freckles were found in 44.4%
of the participants; 12.6% had many.
Relationship of inherited genetic variants to BRAF/NRAS
subtypes
Details of those successfully genotyped for each of the 47
SNPs—number of participants (out of 1,223), chromosomal
location, minor/major alleles, minor allele frequency—are
reported in Supplementary Table S1 online.
For each SNP, associations with melanoma subtypes are
given in Table 2. IRF4 rs12203592 was associated with BRAF/
NRAS mutational subtype (Pglobal ¼ 0.001), and this associ-
ation passed the false discovery threshold (Pglobal ¼ 0.0026).
The odds ratio (ORs) for the association of rs12203592*T
were 0.59 (95% confidence interval [CI] ¼ 0.43e0.79) for
BRAF V600E, 0.65 (95% CI ¼ 0.41e1.03) for BRAF V600K,
1.57 (95% CI ¼ 0.93e2.65) for BRAF other, and 0.99 (95%
CI ¼ 0.75e1.30) for NRASþ, relative to WT melanoma.
PLA2G6 rs132985 and rs738322 had low P-values for their
associations with BRAF/NRAS mutational subtype (Pglobal ¼
0.005 and 0.02, respectively), which did not pass the false
discovery threshold. rs132985*T was associated with BRAF
V600E (OR ¼ 1.32, 95% CI ¼ 1.05e1.67) and BRAF other
(OR ¼ 1.82, 95% CI ¼ 1.11e2.98), but not BRAF V600K orNRASþ melanoma. Similarly, rs738322*G was associated
with BRAF V600E (OR ¼ 1.28, 95% CI ¼ 1.02e1.60) and
BRAF other (OR ¼ 1.66, 95% CI ¼ 1.01e2.72), but not BRAF
V600K or NRASþ melanoma. In a stepwise logistic regres-
sion model including these two SNPs and adjusting for study
features, rs132985 remained associated with melanoma
mutational subtype and was selected for further modeling.
Of the haplotypes examined for the genes with at least
two SNPs genotyped belonging to the same haplotype
block, no haplotypes reached global significancewww.jidonline.org 2399
Table 2. Association of SNPs with melanoma BRAF/NRAS subtypes in the GEM Study1
Chrom Gene region SNP a/A
Compared with WT melanoma
BRAF V600E BRAF V600K BRAF other NRASD Global
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) P-value
1 ARNT rs7412746 C/T 1.12 (0.89e1.40) 1.00 (0.70e1.43) 0.65 (0.38e1.11) 1.11 (0.87e1.42) 0.37
1 PARP1 rs3219090 A/G 1.00 (0.78e1.27) 1.03 (0.70e1.51) 0.78 (0.45e1.35) 0.99 (0.76e1.30) 0.93
1 PARP1 rs2695238 C/G 0.96 (0.75e1.23) 0.90 (0.61e1.32) 0.69 (0.39e1.23) 1.02 (0.78e1.32) 0.75
1 NID1 rs3768080 G/A 1.06 (0.83e1.33) 1.03 (0.72e1.47) 0.90 (0.55e1.48) 1.01 (0.79e1.29) 0.98
1 NID1 rs10754833 C/T 1.03 (0.81e1.30) 0.99 (0.70e1.42) 0.87 (0.53e1.43) 1.01 (0.79e1.29) 0.98
2 CASP8 rs6735656 G/T 1.08 (0.84e1.40) 1.28 (0.87e1.87) 1.70 (1.02e2.81) 1.11 (0.85e1.46) 0.23
2 CASP8 rs13016963 A/G 1.04 (0.82e1.31) 1.00 (0.69e1.43) 1.52 (0.95e2.44) 0.90 (0.70e1.15) 0.39
5 TERT rs2242652 T/C 1.06 (0.80e1.42) 1.26 (0.82e1.93) 1.12 (0.61e2.07) 0.69 (0.49e0.97) 0.14
5 TERT rs2853676 A/G 0.98 (0.76e1.25) 1.25 (0.86e1.81) 0.96 (0.56e1.65) 0.91 (0.69e1.18) 0.69
5 TERT rs13356727 G/A 0.95 (0.75e1.20) 0.65 (0.45e0.94) 0.87 (0.53e1.41) 0.92 (0.72e1.18) 0.24
5 TERT;CLPTM1L rs4975616 G/A 0.95 (0.75e1.22) 0.60 (0.41e0.89) 0.85 (0.50e1.44) 0.94 (0.73e1.22) 0.15
5 TERT;CLPTM1L rs401681 T/C 1.00 (0.79e1.26) 0.60 (0.42e0.88) 0.74 (0.45e1.22) 0.96 (0.75e1.23) 0.08
5 SLC45A2 rs16891982 C/G 0.84 (0.40e1.79) Nonestimable Nonestimable 0.41 (0.10e1.69) 0.81
5 SLC45A2 rs35391 T/C 0.54 (0.19e1.56) Nonestimable Nonestimable 0.65 (0.16e2.63) 0.83
5 SLC45A2 rs26722 T/C 0.74 (0.22e2.53) Nonestimable Nonestimable 0.90 (0.19e4.16) 0.99
5 SLC45A2 rs13289 G/C 0.97 (0.77e1.22) 0.68 (0.46e0.99) 0.71 (0.43e1.18) 0.79 (0.62e1.01) 0.09
6 IRF4 rs12203592 T/C 0.59 (0.43e0.79) 0.65 (0.41e1.03) 1.57 (0.93e2.65) 0.99 (0.75e1.30) 0.001
6 IRF4 rs872071 A/G 1.04 (0.83e1.31) 1.17 (0.82e1.67) 0.51 (0.30e0.89) 1.03 (0.81e1.32) 0.14
9 TYRP1 rs1408799 T/C 1.04 (0.82e1.33) 1.13 (0.78e1.63) 0.84 (0.49e1.46) 0.86 (0.66e1.12) 0.66
9 TYRP1 rs2733832 C/T 0.97 (0.77e1.22) 1.10 (0.77e1.56) 0.98 (0.60e1.61) 0.99 (0.77e1.27) 0.98
9 MTAP rs2218220 T/C 0.90 (0.71e1.13) 0.79 (0.55e1.12) 0.87 (0.54e1.43) 0.85 (0.66e1.08) 0.48
9 MTAP rs1335510 G/T 0.87 (0.69e1.10) 0.75 (0.51e1.08) 0.94 (0.58e1.54) 0.86 (0.67e1.11) 0.41
9 MTAP rs7023329 G/A 0.91 (0.72e1.14) 0.95 (0.66e1.35) 1.03 (0.64e1.68) 0.92 (0.72e1.18) 0.90
9 MTAP rs10811629 G/A 0.84 (0.67e1.06) 0.83 (0.58e1.19) 0.88 (0.53e1.44) 1.07 (0.84e1.36) 0.43
11 CCND1 rs11604821 G/A 0.92 (0.72e1.17) 0.89 (0.61e1.30) 0.77 (0.45e1.30) 0.95 (0.73e1.23) 0.82
11 CCND1 rs1485993 T/C 0.94 (0.75e1.19) 0.91 (0.63e1.31) 0.75 (0.44e1.27) 0.95 (0.74e1.22) 0.83
11 CCND1 rs11263498 T/C 0.92 (0.73e1.16) 0.88 (0.61e1.28) 0.65 (0.38e1.13) 0.95 (0.74e1.23) 0.57
11 TYR rs1042602 A/C 1.26 (1.00e1.59) 1.09 (0.76e1.58) 1.61 (0.99e2.62) 1.00 (0.78e1.29) 0.14
11 TYR rs10765198 C/T 0.93 (0.74e1.17) 1.13 (0.79e1.61) 0.91 (0.54e1.53) 1.04 (0.81e1.33) 0.88
11 TYR rs1847142 A/G 0.97 (0.78e1.22) 1.03 (0.72e1.47) 0.83 (0.49e1.39) 0.97 (0.76e1.25) 0.96
11 TYR rs10830253 G/T 1.01 (0.80e1.27) 1.06 (0.74e1.52) 0.83 (0.49e1.39) 1.00 (0.78e1.29) 0.96
11 ATM rs12278954 A/C 0.98 (0.72e1.34) 0.87 (0.53e1.45) 1.03 (0.53e2.00) 0.89 (0.63e1.26) 0.96
15 OCA2 rs1800407 A/G 1.03 (0.68e1.55) 0.80 (0.40e1.62) 1.38 (0.65e2.92) 1.36 (0.92e2.00) 0.48
15 OCA2 rs1800401 T/C 0.94 (0.54e1.63) 0.73 (0.26e2.01) 0.34 (0.05e2.48) 0.71 (0.36e1.38) 0.68
15 HERC2 rs1129038 G/A 0.82 (0.61e1.09) 0.98 (0.64e1.51) 1.35 (0.78e2.34) 0.90 (0.66e1.21) 0.44
15 HERC2 rs12913832 A/G 0.80 (0.60e1.07) 1.02 (0.67e1.56) 1.34 (0.78e2.31) 0.84 (0.62e1.14) 0.31
20 ASIP rs17305657 C/T 0.87 (0.60e1.27) 1.34 (0.80e2.24) 0.80 (0.34e1.90) 0.80 (0.52e1.21) 0.49
20 ASIP rs4911414 T/G 1.00 (0.79e1.28) 1.22 (0.85e1.76) 1.45 (0.88e2.38) 1.09 (0.85e1.41) 0.50
20 PIGU rs910873 A/G 0.87 (0.60e1.26) 1.02 (0.60e1.76) 0.73 (0.32e1.64) 1.03 (0.71e1.49) 0.87
20 PIGU rs17305573 C/T 0.84 (0.58e1.24) 1.07 (0.62e1.84) 0.77 (0.34e1.74) 0.98 (0.67e1.44) 0.87
20 NCOA6 rs4911442 G/A 0.89 (0.65e1.23) 1.16 (0.73e1.84) 0.60 (0.28e1.28) 0.88 (0.63e1.24) 0.54
20 MYH7B rs1885120 C/G 0.79 (0.53e1.17) 1.07 (0.61e1.87) 0.84 (0.37e1.90) 0.94 (0.64e1.39) 0.78
20 LOC647979 rs1204552 A/T 0.91 (0.60e1.37) 0.67 (0.33e1.36) 0.96 (0.43e2.18) 0.75 (0.47e1.17) 0.62
21 MX2 rs45430 G/A 0.91 (0.71e1.15) 0.83 (0.56e1.21) 0.41 (0.22e0.78) 0.95 (0.74e1.23) 0.07
22 PLA2G6 rs6001027 G/A 1.11 (0.87e1.42) 0.99 (0.67e1.45) 1.91 (1.14e3.20) 0.85 (0.64e1.11) 0.06
22 PLA2G6 rs132985 T/C 1.32 (1.05e1.67) 1.12 (0.78e1.60) 1.82 (1.11e2.98) 0.83 (0.64e1.07) 0.005
22 PLA2G6 rs738322 G/A 1.28 (1.02e1.60) 1.09 (0.76e1.55) 1.66 (1.01e2.72) 0.84 (0.66e1.08) 0.02
Abbreviations: a, minor allele; A, major allele; Chrom, chromosome; CI, confidence interval; GEM, Genes, Environment and Melanoma; OR, odds ratio;
SNP, single-nucleotide polymorphism; WT, wild type (BRAFe/NRASe).
1Limited to individuals of European origin. Bold type indicates P-values < 0.05. We used multinomial logistic regression to estimate the ORs and 95% CIs
with somatic BRAF/NRASmutational subtypes simultaneously compared with WT melanoma, adjusted for study features: age at diagnosis (continuous), sex,
study center, and whether first- or higher-order primary melanoma. The per-allele OR (based on the minor allele) and P-values referring to the global test for
etiologic heterogeneity are provided.
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Table 3. IRF4 rs12203592 and PLA2G6 rs132985 associations with melanoma BRAF/NRAS subtypes adjusted for
study features and then also adjusted for potential phenotypic mediators1
SNP
Compared with WT melanoma
BRAF V600E BRAF V600K BRAF other NRASD
Global P-valueOR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
IRF4 rs12203592*T2
Adjusted for study features3 0.61 (0.45e0.83) 0.64 (0.40e1.03) 1.67 (0.98e2.84) 1.01 (0.76e1.34) 0.002
Adjusted for study features and nevi 0.62 (0.45e0.85) 0.69 (0.42e1.11) 1.69 (0.98e2.91) 1.06 (0.79e1.41) 0.003
Adjusted for study features and hair color 0.65 (0.47e0.90) 0.60 (0.36e0.99) 1.71 (0.99e2.96) 0.97 (0.72e1.30) 0.006
Adjusted for study features and freckling 0.63 (0.46-0.87) 0.78 (0.48e1.28) 1.57 (0.90e2.72) 1.01 (0.75e1.36) 0.02
Adjusted for study features, nevi, hair color, and freckling4 0.68 (0.48e0.96) 0.79 (0.46e1.34) 1.52 (0.84e2.75) 0.99 (0.72e1.35) 0.10
PLA2G6 rs132985*T5
Adjusted for study features3 1.31 (1.04e1.66) 1.10 (0.76e1.59) 1.94 (1.17e3.21) 0.83 (0.64e1.07) 0.004
Adjusted for study features and nevi 1.32 (1.04e1.67) 1.10 (0.76e1.59) 1.93 (1.17e3.21) 0.84 (0.65e1.08) 0.006
Adjusted for study features and hair color 1.32 (1.04e1.67) 1.11 (0.77e1.61) 1.96 (1.19e3.25) 0.83 (0.65e1.08) 0.004
Adjusted for study features and freckling 1.31 (1.03e1.66) 1.10 (0.76e1.59) 1.95 (1.17e3.25) 0.83 (0.64e1.07) 0.005
Adjusted for study features, nevi, hair color, and freckling4 1.32 (1.04e1.67) 1.10 (0.76e1.60) 1.99 (1.20e3.32) 0.84 (0.65e1.09) 0.005
Abbreviations: CI, confidence interval; GEM, Genes, Environment and Melanoma; OR, odds ratio; WT, wild type (BRAFe/NRASe).
1Bold type indicates P-values < 0.05. We used multinomial logistic regression to estimate the ORs and 95% CIs with BRAF/NRAS mutational subtypes
simultaneously compared with WT melanoma. The per-allele OR (based on the minor allele) and P-values referring to the global test for etiologic het-
erogeneity are provided.
2Limited to 1,136 individuals of European origin who had no missing data for the IRF4 rs12203592 genotype or the phenotypes. The distribution of the
melanoma subtypes was WT (n ¼ 682), BRAF V600E (n ¼ 199), BRAF V600K (n ¼ 64), BRAF other (n ¼ 33), and NRASþ (n ¼ 158). Participants with one or
more data points missing for rs12203592 genotype (n ¼ 24), number of back nevi (n ¼ 20), hair color (n ¼ 3), or freckling (n ¼ 49) were excluded.
3Adjusted for study features: age at diagnosis (continuous), sex, study center, and whether first- or higher-order primary melanoma.
4Adjusted for study features and phenotype: number of back nevi (0e4, 5e10, 11e25, >25), hair color (dark brown/black, blonde/light brown, red), and
freckling (none, few, many).
5Limited to 1,139 individuals of European origin who had no missing data for the PLA2G6 rs132985 genotype or the phenotypes. The distribution of the
melanoma subtypes was WT (n ¼ 683), BRAF V600E (n ¼ 203), BRAF V600K (n ¼ 63), BRAF other (n ¼ 33), and NRASþ (n ¼ 157). Participants with one or
more data points missing for rs132985 genotype (n ¼ 21), number of back nevi (n ¼ 20), hair color (n ¼ 3), or freckling (n ¼ 49) were excluded.
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Inherited Variants and Melanoma BRAF/NRAS Subtypes(Supplementary Table S2 online). Evaluation of the haplotype
blocks and linkage disequilibrium patterns for IRF4 using
both the GEM data and the Hapmap CEU population
revealed that the two IRF4 SNPs were in different haplotype
blocks; therefore, haplotype analysis did not apply to IRF4.
We had previously found that a number of back nevi, hair
color, and freckling were associated with BRAF/NRAS sub-
type (Thomas et al., 2017), indicating that these phenotypes
could be mediators of genotype associations with BRAF/
NRAS subtype. To further explore this possibility, we exam-
ined, in participants with tumor BRAF/NRAS subtype
analyzed, whether IRF4 rs12203592 or PLA2G6 rs132985
genotypes were associated with these phenotypes in models
adjusted for study features (Supplementary Tables S3 online).
rs12203592*T was significantly associated with fewer back
nevi, darker hair color, and less freckling (all Pglobal < 0.001).
rs132985 was not significantly associated with back nevi,
hair color, or freckling.
Next, we built multivariable models for each SNP that
included these three phenotypes, first examining the associ-
ation of each SNP with BRAF/NRAS subtype adjusted for
study features, and then adding back nevi, hair color, and
freckling, separately and then together to the models
(Table 3). In the models for IRF4 rs12203592, the ORs for all
three BRAF subtypes were attenuated as the phenotypes were
progressively added to the model; in the model that included
all factors, the global test for etiologic heterogeneity was not
significant (Pglobal ¼ 0.10). When examining the associationsof PLA2G6 rs132985 with BRAF/NRAS subtypes, the OR of
rs132985*T for BRAF V600E remained the same or similar in
all the models. The OR of rs132985*T for BRAF other exon
15 mutations increased from 1.94 in the model adjusted for
study features only to 1.99 in the fully adjusted model. The
global tests for etiologic heterogeneity remained nominally
significant.
DISCUSSION
Passing false discovery, IRF4 rs12203592*T was inversely
associated with melanoma carrying BRAF V600E and V600K
somatic mutations relative to WT melanoma. We, like others
(Duffy et al., 2010a, 2010b; Han et al., 2008; Zhang et al.,
2013), found rs12203592*T to be associated with fewer
nevi, darker hair color, and increased freckles. Previously, we
reported that increased nevi were associated with BRAF
V600E and V600K; lighter hair color with BRAF V600E; and
decreased freckling with BRAF V600K compared with WT
melanoma (Thomas et al., 2017). Hacker et al. (2016) also
found increased nevi to be associated with BRAF V600E and
V600K vs. WT melanoma. Thus, these associations are in the
directions expected for potential mediation by these pheno-
types of the associations of rs12203592 with BRAF subtypes.
The IRF4 rs12203592 associations with BRAF subtypes were
attenuated after adjustment for these three phenotypes, and
these results suggest that a substantial portion of the impact of
rs12203592 is mediated through these phenotypes or their
underlying genotypes.www.jidonline.org 2401
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rs132985*T with somatic BRAF V600E and BRAF other so-
matic mutations relative to WT melanoma. The literature
supports that rs132985*C is positively associated with both
nevus counts and melanoma risk (Duffy et al., 2017; Falchi
et al., 2009; Fang et al., 2013; Kvaskoff et al., 2011). Falchi
et al. (2009) explored whether nevus count mediated the
association between rs132985 and melanoma and reported
attenuation of the melanoma OR when adding nevus count
to their model. Because of these findings and BRAF V600’s
known association with increased nevi (Hacker et al., 2016;
Thomas et al., 2007, 2017), it might have been expected that
PLA2G6 rs132985*C would have been positively associated
with BRAF subtypes. However, instead, we found a positive
association with rs132985*T. Also, the associations of
rs132985 with BRAF subtypes reported here in GEM were
overall independent of the number of nevi, hair color, and
freckling. Thus, the evidence provided here indicates that the
associations of rs132985 with BRAF subtypes are not medi-
ated by phenotypes. Possibly, the associations could instead
be mediated by the reported apoptotic effects of the PLA2G6
gene (Akiba and Sato, 2004).
Our study’s strengths are its population-based design, large
sample size, and rigorous mutational analysis of BRAF and
NRAS mutations. The study limitations include low numbers
of BRAF V600K and BRAF other subtypes, limiting statistical
power. It is possible that the power of the study was insuffi-
cient to detect the associations of some of the other SNPs
tested with BRAF/NRAS subtypes. Also, we investigated a
limited number of melanoma-riskeassociated genotypes and
others remain to be tested in relationship to BRAF/NRAS
subtypes (Duffy et al., 2017; Iles et al., 2013; Law et al.,
2015). Our findings remain to be replicated.
Our results provide a link between the genetics of the
person and somatic genetic data in melanoma to gain an
understanding of how the genetics of both the person and the
tumor interact. Our findings suggest roles for inherited IRF4
and PLA2G6 polymorphisms in the development of BRAF/
NRAS melanoma subtypes and that these roles have different
underlying mechanisms. Although our work indicates that
IRF4’s associations are mediated by specific phenotypes,
further investigation of factors underlying PLA2G6’s associ-
ations with subtype is needed. Larger studies or pooled an-
alyses and studies including more inherited melanoma-risk
variants may provide additional insight into the development
of melanoma molecular subtypes, further defining their risk
factors and providing information that may lead toward
improved prevention of this complex disease.
MATERIALS AND METHODS
Study population
Details concerning the GEM study population, genotyping, and
BRAF/NRAS mutational subtyping have been published previously
(Begg et al., 2005; Gibbs et al., 2015, 2016, 2017; Thomas et al.,
2015, 2017; Vernali et al., 2017). Patient characteristics were
collected via phone interviews and self-completed questionnaires
(Kricker et al., 2007; Thomas et al., 2007, 2010b). We collected
patients’ self-reported number of back nevi counted by a family
member or friend, a measure that has been reported in other studies
as predictive of total body nevus counts (Autier et al., 2001; EnglishJournal of Investigative Dermatology (2018), Volume 138and Armstrong, 1994; English et al., 1988). GEM’s 3,579 participants
had first- or higher-order primary melanoma diagnosed between
1998 and 2003 in Australia, Canada, Italy, and the United States
(Begg et al., 2004, 2006; Millikan et al., 2006; Murali et al., 2012;
Orlow et al., 2007). The institutional review board at each partici-
pating site approved the study protocol. Study participants provided
written informed consent. Diagnostic slides were reviewed centrally
for histopathologic criteria (Thomas et al., 2010b, 2013, 2014,
2015). We sought tissue sections from 2,116 participants’ first- or
higher-order incident invasive primary melanomas diagnosed in
New South Wales (Australia), California, North Carolina, and
Michigan. Of these 2,116 GEM participants, 1,227 (58%) had
formalin-fixed, paraffin-embedded melanoma tissues obtained and
analyzed for BRAF exon 15 (including codon 600) and NRAS exon 2
and 3 (including codons 61, 12, and 13) mutations using single-
strand conformational polymorphism analysis and radiolabeled
sequencing of single-strand conformational polymorphism-positive
samples (Thomas et al., 2007, 2015). Of these 1,227 patients, we
limited the analyses presented here to the 1,223 participants of Eu-
ropean origin. We previously reported the associations of BRAF/
NRAS subtypes with age, sex, tumor characteristics, and survival for
912 GEM first primaries (Thomas et al., 2015), with phenotype and
MC1R for 1,227 participants (Thomas et al., 2017), and with age,
sex, and phenotype in 214 GEM first primaries from North Carolina
(Thomas et al., 2007) and 88 from Michigan (Poynter et al., 2006).
Genotyping
We selected 47 SNPs from 21 loci based on evidence that they were
low-penetrant risk variants formelanoma in other studies (Amos et al.,
2011; Barrett et al., 2011; Bishop et al., 2009; Fernandez et al., 2008;
Gudbjartsson et al., 2008; Han et al., 2008; Jannot et al., 2005;
Law et al., 2012; Macgregor et al., 2011; Nan et al., 2011; Zhang
et al., 2012). DNA was extracted from buccal swab kits (Begg et al.,
2005). SNPs were genotyped using the MassArray iPLEX platform
(Agena Bioscience, San Diego, CA) with quality control measures
described previously (Orlow et al., 2012). CASP8 rs10931936 and
ATM rs1801516 (Barrett et al., 2011) were not compatible with the
platform design, and proxy SNPs rs6735656 and rs12278954,
respectively (r2 > 0.95), were chosen (1000 Genomes, CEU popula-
tion; Proxy SNP; Broad Institute).
Statistical analysis
The melanomas were grouped as BRAF V600E, BRAF V600K, BRAF
other (exon 15 mutations besides V600E and V600K), NRASþ (exon
2 or 3 mutation), or WT (wild-type negative for these mutations).
Assuming an additive model of inheritance of the minor allele for
each SNP, multinomial logistic regression models were used to es-
timate simultaneously the OR and 95% CI with BRAF V600E, BRAF
V600K, BRAF other, and NRASþ, compared with WT (BRAFe/
NRASe) melanoma adjusted for study features: age at diagnosis
(continuous), sex, study center, whether first or higher order primary.
Some analyses were also adjusted for phenotypes. Statistical signif-
icance was assessed using Wald tests. The false discovery threshold
adjusted for multiple comparisons was computed using a resampling
method that takes into account the linkage disequilibrium informa-
tion among SNPs evaluated and is less conservative than the clas-
sical Bonferroni procedure (He et al., 2013; Lin, 2005).
For the genes with at least two SNPs genotyped, we first deter-
mined their haplotype blocks using the Haploview software algo-
rithm, as previously described (Gibbs et al., 2015). Each haplotype
or grouped rare haplotypes were then compared with the most
NE Thomas et al.
Inherited Variants and Melanoma BRAF/NRAS Subtypescommon haplotypes in our study population. Some associations
could not be examined because of low genotype minor allele fre-
quencies or infrequent haplotypes in some subtype categories and
noted as nonestimable in the tables. For the two nominally signifi-
cantly associated SNPs in the PLA2G6 locus, we applied stepwise
logistic regression to determine the SNP with the stronger associa-
tion keeping study features fixed.
We examined the relationship between the significantly associ-
ated genotypes and BRAF/NRAS subtype for potential mediation by
phenotypes (back nevi, hair color, and freckling) associated in GEM
with BRAF/NRAS subtype (Thomas et al., 2017). Using multinomial
logistic regression adjusted for study features, we estimated the as-
sociations of the genotypes with these phenotypes limited to par-
ticipants of European origin who had no missing data for the
genotype, BRAF/NRAS subtype, or these phenotypes. Next, we used
multivariable models for each SNP to examine its associations with
BRAF/NRAS subtypes, adding the phenotypes separately and then
together to models. All analytic models were adjusted for study
features. All tests were two-sided with P < 0.05 considered statisti-
cally significant. All data were analyzed using SAS 9.4 (Cary, NC) or
R (http://www.r-project.org/) programs.
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